Literature DB >> 30827108

Ursolic Acid Isolated from the Leaves of Loquat ( Eriobotrya japonica) Inhibited Osteoclast Differentiation through Targeting Exportin 5.

Hui Tan1, Chong Zhao2, Qinchang Zhu3, Yoshinori Katakura4, Hiroyuki Tanaka5, Koichiro Ohnuki6, Kuniyoshi Shimizu7.   

Abstract

One of the conventional strategies for treating osteoporosis is to eliminate the multinucleated osteoclasts that are responsible for bone resorption. Our previous study revealed that ursolic acid, isolated from leaves of loquat that is used as tasty tea in Japan, suppressed osteoclastogenesis. We confirmed that ursolic acid exhibited osteoclast differentiation inhibitory activity with an 50% inhibitory concentration (IC50) value of 5.4 ± 0.96 μM. To disclose its mechanism of action, this study first uses polymer-coated magnetic nanobeads to identify potential target proteins. As a result, we identified a nuclear exporter protein named exportin 5 (XPO5). Further studies demonstrated that knockdown of XPO5 significantly blocks osteoclast differentiation ( P < 0.01). Expression profiling of mature microRNAs in the cells revealed that downregulation of XPO5 by small interfering RNA or by ursolic acid could downregulate the expression of mature microRNA let-7g-5p during osteoclast differentiation ( P < 0.01). Collectively, our findings suggest that ursolic acid inhibits osteoclast differentiation through targeting XPO5, which provides further evidence for the healthy function of the tea. This study also provides new insights into the role of XPO5 and its mediated microRNAs in treatment for bone resorption diseases.

Entities:  

Keywords:  exportin 5; let-7g-5p; microRNAs; osteoporosis; ursolic acid

Mesh:

Substances:

Year:  2019        PMID: 30827108     DOI: 10.1021/acs.jafc.8b06954

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  7 in total

Review 1.  Evolving Roles of Natural Terpenoids From Traditional Chinese Medicine in the Treatment of Osteoporosis.

Authors:  Yue Zhuo; Meng Li; Qiyao Jiang; Hanzhong Ke; Qingchun Liang; Ling-Feng Zeng; Jiansong Fang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-16       Impact factor: 6.055

2.  Polyploidy underlies co-option and diversification of biosynthetic triterpene pathways in the apple tribe.

Authors:  Wenbing Su; Yi Jing; Shoukai Lin; Zhen Yue; Xianghui Yang; Jiabao Xu; Jincheng Wu; Zhike Zhang; Rui Xia; Jiaojiao Zhu; Ning An; Haixin Chen; Yanping Hong; Yuan Yuan; Ting Long; Ling Zhang; Yuanyuan Jiang; Zongli Liu; Hailan Zhang; Yongshun Gao; Yuexue Liu; Hailan Lin; Huicong Wang; Levi Yant; Shunquan Lin; Zhenhua Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-18       Impact factor: 11.205

Review 3.  Ursolic Acid-Based Derivatives as Potential Anti-Cancer Agents: An Update.

Authors:  Vuyolwethu Khwaza; Opeoluwa O Oyedeji; Blessing A Aderibigbe
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

4.  Predicting and Exploring the Mechanisms of Erzhi Pill in Prevention and Treatment of Osteoporosis Based on Network Pharmacology and Zebrafish Experiments.

Authors:  Zhiguo Zhong; Yuyun Li; Yan Chen; Wen Chen; Siyan Li; Xiaohua Lv; Shiying Luo
Journal:  Drug Des Devel Ther       Date:  2021-02-24       Impact factor: 4.162

5.  Ursolic Acid Loaded-Mesoporous Hydroxylapatite/ Chitosan Therapeutic Scaffolds Regulate Bone Regeneration Ability by Promoting the M2-Type Polarization of Macrophages.

Authors:  Xijiao Yu; Yuxuan Wang; Xiaoliang Liu; Yuwei Ge; Shanyong Zhang
Journal:  Int J Nanomedicine       Date:  2021-08-06

Review 6.  Traditional Chinese Medicine Compound-Loaded Materials in Bone Regeneration.

Authors:  Guiwen Shi; Chaohua Yang; Qing Wang; Song Wang; Gaoju Wang; Rongguang Ao; Dejian Li
Journal:  Front Bioeng Biotechnol       Date:  2022-02-18

7.  Research on the Mechanism of Liuwei Dihuang Decoction for Osteoporosis Based on Systematic Biological Strategies.

Authors:  Zhi-Yong Long; Jia-Min Wu; Wang Xiang; Meng-Xia Yuan; Yong-He Wu; Jun Li; Gan-Peng Yu; Tiejun Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-22       Impact factor: 2.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.